Latest Ratios: P/E Ratio -1.2x · EV/EBITDA N/A · ROE -79.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $182M | $148M | $144M | $423M | $382M | $909M | — | — |
| Enterprise Value | $196M | $163M | $154M | $399M | $351M | $669M | — | — |
| P/E Ratio → | -1.15 | — | — | — | — | — | — | — |
| P/S Ratio | 16.26 | 13.31 | 14.37 | 12.27 | 27.57 | 94.75 | — | — |
| P/B Ratio | 1.40 | 1.22 | 0.57 | 1.15 | 1.27 | 2.34 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.64 | 15.39 | 11.57 | 25.36 | 69.70 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.3% | 67.3% | 60.7% | 89.8% | 73.7% | 89.7% | -178.5% | 100.0% |
| Operating Margin | -1220.5% | -1220.5% | -1667.2% | -336.6% | -768.2% | -697.8% | -292.2% | -592.7% |
| Net Profit Margin | -1327.4% | -1327.4% | -1491.9% | -296.1% | -717.8% | -697.3% | -277.6% | -404.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -79.0% | -79.0% | -48.0% | -30.5% | -28.9% | -36.7% | — | -314.0% |
| ROA | -60.6% | -60.6% | -40.0% | -25.3% | -24.4% | -28.0% | -70.0% | -37.8% |
| ROIC | -51.0% | -51.0% | -41.1% | -28.3% | -38.2% | -91.5% | — | — |
| ROCE | -63.0% | -63.0% | -48.5% | -31.0% | -27.9% | -30.4% | -95.7% | -66.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.10 | 0.07 | 0.09 | 0.00 | — | 0.07 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.12 | 0.04 | -0.07 | -0.10 | -0.62 | — | -5.43 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -8324.25 | -1805.35 | -7741.00 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.71 | 5.71 | 7.16 | 11.97 | 9.25 | 15.15 | 1.96 | 5.66 |
| Quick Ratio | 5.71 | 5.71 | 7.16 | 11.97 | 9.25 | 15.15 | 1.96 | 5.66 |
| Cash Ratio | 5.48 | 5.48 | 6.84 | 11.62 | 8.80 | 14.55 | 1.29 | 4.91 |
| Asset Turnover | — | 0.06 | 0.03 | 0.08 | 0.04 | 0.02 | 0.34 | 0.09 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 97.44 | 118.73 | 40.85 | 122.91 | 308.95 | 152.37 | 251.11 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $93M | $90M | $74M | $61M | $60M | $28M | $28M |
Imminent liquidity shortfall
As reported in financial statements, Caribou trades at a price-to-sales multiple of 14.93, a valuation that appears to prioritize the long-term potential of the chRDNA platform over current financial performance, given the company's lack of commercial product revenue and reliance on volatile, milestone-based partnership income streams.
The elevated P/S ratio suggests that investors are pricing the firm as a speculative technology play rather than a traditional healthcare entity. This valuation implies significant market optimism regarding the clinical success of CB-010, yet it remains highly sensitive to any delays in the development pipeline that could force further dilutive capital raises.
Based on the provided quarterly data, the company's ROIC has consistently remained in negative territory, deteriorating to -15.5% in 2026Q1, which underscores the structural challenge of generating positive returns on invested capital while the firm remains in a high-burn, pre-revenue clinical development phase.
The persistent negative ROIC reflects the heavy expenditure on clinical trials and personnel relative to the limited revenue generated from collaboration agreements. This trend suggests that until the company can transition toward a commercialized product, capital efficiency will likely remain suppressed by the necessity of ongoing, non-revenue-generating research investments.
According to recent SEC filings, the company's asset turnover ratio remains extremely low at 0.01, indicating that the firm's current asset base is not being utilized to generate meaningful revenue, which is typical for a clinical-stage biotech firm focused on long-term intellectual property development.
The erratic nature of the cash conversion cycle, coupled with high DSO figures, suggests that the timing of milestone payments from partners like AbbVie creates significant lumpiness in liquidity. Investors should monitor these metrics as indicators of the company's ability to manage its limited working capital effectively during periods of high clinical activity.
As indicated by the reported figures, the current ratio has compressed from 11.97 in 2023Q4 to 6.22 in 2026Q1, reflecting a rapid depletion of liquid assets that warrants close investigation regarding the company's ability to sustain its current clinical trial trajectory without immediate external financing.
While a current ratio of 6.22 might appear healthy in isolation, the absolute cash balance of $12.36 million is insufficient to cover the high quarterly operating losses observed in recent periods. This suggests that the company's liquidity position is increasingly vulnerable to even minor disruptions in its partnership-based funding model.
Based on reported figures, the most commonly misapplied metric for Caribou is the gross margin, which, at 72.9% in 2026Q1, obscures the reality that these margins are derived from service-based R&D reimbursements rather than a scalable, high-margin manufacturing process for commercialized therapeutic products.
Analysts should avoid using these margins to project future profitability, as they do not account for the eventual cost of goods sold that will emerge upon commercialization. A more appropriate focus would be the net cash burn rate, which provides a clearer picture of the company's actual financial sustainability.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRBU stock.
Caribou Biosciences, Inc.'s current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
Caribou Biosciences, Inc.'s return on equity (ROE) is -79.0%. The historical average is -89.5%.
Based on historical data, Caribou Biosciences, Inc. is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Caribou Biosciences, Inc. has 67.3% gross margin and -1220.5% operating margin.